

Katarina Le Blanc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1780794/publications.pdf>

Version: 2024-02-01

50
papers

10,240
citations

230014

27
h-index

274796

44
g-index

50
all docs

50
docs citations

50
times ranked

12127
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. <i>Lancet, The</i> , 2004, 363, 1439-1441.	6.3	2,534
2	Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. <i>Lancet, The</i> , 2008, 371, 1579-1586.	6.3	2,474
3	HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. <i>Experimental Hematology</i> , 2003, 31, 890-896.	0.2	1,510
4	Multipotent mesenchymal stromal cells and the innate immune system. <i>Nature Reviews Immunology</i> , 2012, 12, 383-396.	10.6	811
5	Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 321-334.	2.0	429
6	Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta. <i>Transplantation</i> , 2005, 79, 1607-1614.	0.5	397
7	CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. <i>Blood</i> , 2014, 124, 750-760.	0.6	206
8	Mesenchymal stromal cells and the innate immune response. <i>Immunology Letters</i> , 2015, 168, 140-146.	1.1	204
9	Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. <i>Current Opinion in Immunology</i> , 2006, 18, 586-591.	2.4	202
10	In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. <i>Stem Cells Translational Medicine</i> , 2015, 4, 1199-1213.	1.6	131
11	Challenges for mesenchymal stromal cell therapies. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	126
12	Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. <i>Cell Stem Cell</i> , 2021, 28, 1708-1725.	5.2	114
13	Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 3849-3859.	3.2	109
14	Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1108-1115.	2.0	100
15	MSCsâ€”cells with many sides. <i>Cytotherapy</i> , 2018, 20, 273-278.	0.3	91
16	Stromal cellâ€”mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling. <i>Blood</i> , 2015, 125, 3432-3436.	0.6	76
17	A low body mass index is correlated with poor survival after allogeneic stem cell transplantation. <i>Haematologica</i> , 2003, 88, 1044-52.	1.7	62
18	Do ABO Blood Group Antigens Hamper the Therapeutic Efficacy of Mesenchymal Stromal Cells?. <i>PLoS ONE</i> , 2014, 9, e85040.	1.1	61

#	ARTICLE	IF	CITATIONS
19	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2365-2370.	2.0	61
20	A Comparison of Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2004, 78, 1014-1020.	0.5	59
21	Generation of Immunosuppressive Mesenchymal Stem Cells in Allogeneic Human Serum. <i>Transplantation</i> , 2007, 84, 1055-1059.	0.5	57
22	Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro. <i>Stem Cells Translational Medicine</i> , 2016, 5, 1485-1495.	1.6	51
23	Defined serum-free media for in vitro expansion of adipose-derived mesenchymal stem cells. <i>Cytotherapy</i> , 2014, 16, 915-926.	0.3	48
24	MSC from fetal and adult lungs possess lung-specific properties compared to bone marrow-derived MSC. <i>Scientific Reports</i> , 2016, 6, 29160.	1.6	43
25	Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation. <i>Stem Cells</i> , 2016, 34, 516-521.	1.4	39
26	Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis. <i>Immunology and Cell Biology</i> , 2018, 96, 820-830.	1.0	38
27	Persistence of Human Parvovirus B19 in Multipotent Mesenchymal Stromal Cells Expressing the Erythrocyte P Antigen: Implications for Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1172-1179.	2.0	31
28	Heparinization of cell surfaces with short peptide-conjugated PEG-lipid regulates thromboinflammation in transplantation of human MSCs and hepatocytes. <i>Acta Biomaterialia</i> , 2016, 35, 194-205.	4.1	24
29	Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation. <i>Haematologica</i> , 2005, 90, 438.	1.7	21
30	Wnt/ β -Catenin Stimulation and Laminins Support Cardiovascular Cell Progenitor Expansion from Human Fetal Cardiac Mesenchymal Stromal Cells. <i>Stem Cell Reports</i> , 2016, 6, 607-617.	2.3	20
31	Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosisâ€”A Phase I Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 2102.	1.0	20
32	Consensus International Council for Commonality in Blood Banking Automationâ€”International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. <i>Cytotherapy</i> , 2021, 23, 1060-1063.	0.3	15
33	Myeloid-derived suppressor cells in allogeneic hematopoietic stem cell transplantation. <i>OncImmunology</i> , 2013, 2, e25009.	2.1	13
34	MSCs: Scientific Support for Multiple Therapies. <i>Stem Cells International</i> , 2015, 2015, 1-2.	1.2	12
35	Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 677-683.	2.0	12
36	Five-Year Follow-up after Mesenchymal Stromal Cellâ€”based Treatment of Severe Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1051-1055.	2.5	9

#	ARTICLE	IF	CITATIONS
37	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. Blood, 2006, 108, 5304-5304.	0.6	8
38	Commentary: Role of Mesenchymal Stromal Cell-Mediated Crosstalk with Macrophages in Graft-versus-Host Disease and Tissue Repair. Biology of Blood and Marrow Transplantation, 2017, 23, 861-862.	2.0	7
39	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. Blood, 2006, 108, 2918-2918.	0.6	4
40	Enhanced oral healing following local mesenchymal stromal cell therapy. Oral Oncology, 2015, 51, e97-e99.	0.8	3
41	Mesenchymal Stem Cells for Treatment of Severe Acute and Extensive Chronic Graft-Versus-Host Disease.. Blood, 2005, 106, 143-143.	0.6	3
42	Diversity of respiratory parameters and metabolic adaptation to low oxygen tension in mesenchymal stromal cells. Metabolism Open, 2022, 13, 100167.	1.4	2
43	Immunohistopathology of oral mucosal chronic graft-versus-host disease severity and duration. Oral Diseases, 2023, 29, 3346-3359.	1.5	2
44	Stromal progenitor cell modulation by thalidomide in the treatment of oral chronic graft-versus-host disease. Cytotherapy, 2018, 20, 755-758.	0.3	1
45	Immune Escape and Suppression by Human Mesenchymal Stem Cells. , 2006, , 233-245.		0
46	Transplantation of Haplo-Identical Bone Marrow-Derived Mesenchymal Stem Cells Together with Hematopoietic Stem Cells To Promote Engraftment in Children. A Phase I/II Multicenter Study.. Blood, 2005, 106, 2911-2911.	0.6	0
47	HLA Mismatched MSC Suppress T Lymphocyte Allo responses in Vitro and Do Not Induce Immunological Memory in Recipients of MSC Infusion. Blood, 2008, 112, 4740-4740.	0.6	0
48	Human Mesenchymal Stem Cells Elicit Complement Activation in Human Blood.. Blood, 2009, 114, 4580-4580.	0.6	0
49	Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia. Blood, 2015, 126, 2398-2398.	0.6	0
50	Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation. Blood, 2016, 128, 3374-3374.	0.6	0